DRUG-COATED BALLOONS HEALTHCARE PROFESSIONALS

In.Pact Admiral DCB

In.Pact Admiral

Drug Coated Balloon

Durable.

Consistent.

Safe.

The IN.PACT™ Admiral™ drug-coated balloon (DCB) is a clinically proven, primary endovascular therapy used to treat femoropopliteal disease.

ACCESS PRODUCT OVERVIEW
Healthcare Professional

IN.PACT SFA Trial - Primary Patency Outcomes

IN.PACT SFA Trial –

Primary Patency Outcomes

Primary Patency Outcomes
This

IN.PACT Admiral DCB demonstrates consistent positive outcomes out to 3 years.1

Clinical

Outcomes

IN.PACT Admiral  DCB demonstrates consistent positive outcomes out to 3 years.

VIew Clinical Outcomes

THE SCIENCE

BEHIND THE OUTCOMES

IN.PACT Admiral DCB increases blood flow and reduces thickening of the artery wall by delivering the proven anti-proliferative drug paclitaxel to the vessel wall.

See DCB Technology
INPACT Admiral In Vessel

Cost Effective Solution

~$1,200

Average saved on follow-up costs through 2 years per patient with IN.PACT Admiral versus standard PTA2

$2,984 vs. $4,196

THE COST-EFFECTIVE

SOLUTION

Cost savings from the reduced rates of reintervention and higher rates of clinical efficacy make IN.PACT Admiral DCB the clear choice for patients and physicians. 

View Publication in JACC
Play Video Peripheral Artery Disease: Dr. John Laird, UC Davis Vascular Center

PAD Overview: Dr. John Laird, UC Davis Vascular Center

Play Video Cost-Effectiveness: Dr. David Cohen, University of Missouri-Kansas City

Cost-Effectiveness: Dr. David Cohen, University of Missouri-Kansas City

Play Video How IN.PACT Works: Dr. Renu Virmani, CVPath Institute

How IN.PACT Admiral DCB Works: Dr. Renu Virmani, CVPath Institute

Request Information

Request More

Information

Contact Us

1

Medtronic Data: 1-year Outcomes: IN.PACT Admiral IFU M052624T001 Rev. 1F. 2-year Outcomes: Laird et al, JACC, VOL . 6 6 , NO. 2 1 , 2 0 1 5. 3-year: Krishnan, P.VIVA, 2016. Primary patency is defined as freedom from clinically-driven TLR and freedom from restenosis as determined by DUS PSVR, ≤2.4 Primary Efficacy reported on Kaplan-Meier survival analysis. 

2

Cohen D. Economic Outcomes of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons vs Standard PTA: 2-Year Results From the IN.PACT SFA II Trial. Presented at: VIVA 15; Nov. 2-5, 2015; Las Vegas.